Askgene Pharma Inc.
Records under this name other than the patents Askgene Pharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,059,885 | Novel Angiopoietin 2, VEGF Dual Antagonists now held by Jiangsu Aosaikang Pharmaceutical Co., Ltd. In force · High confidence | In force | High confidence | |
| US 12,043,662 | Novel Angiopoietin 2, VEGF Dual Antagonists now held by Jiangsu Aosaikang Pharmaceutical Co., Ltd. In force · High confidence | In force | High confidence | |
| US 12,715,912 | Novel Angiopoietin 2, VEGF Dual Antagonists now held by Jiangsu Aosaikang Pharmaceutical Co., Ltd. In force · High confidence | In force | High confidence | |
| US 10,654,922 | Novel Angiopoietin 2, VEGF Dual Antagonists now held by Jiangsu Aosaikang Pharmaceutical Co., Ltd. In force · High confidence | In force | High confidence | |
| US 11,746,147 | Novel Angiopoietin 2, VEGF Dual Antagonists now held by Jiangsu Aosaikang Pharmaceutical Co., Ltd. In force · High confidence | In force | High confidence | |
| US 12,312,413 | Novel Antibodies and Methods for Making and Using the Same now held by Jiangsu Aosaikang Pharmaceutical Co., Ltd. In force · Medium confidence | In force | Medium confidence | |
| US 11,505,618 | Novel Antibodies and Methods for Making and Using the Same now held by Jiangsu Aosaikang Pharmaceutical Co., Ltd. In force · Medium confidence | In force | Medium confidence | |
| US 10,287,336 | Novel Feline Erythropoietin Receptor Agonists Lapsed on the fee record Ended May 14, 2023 · High confidence | Lapsed on the fee record | Ended May 14, 2023 | High confidence |
| US 10,077,308 | PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis Lapsed on the fee record Ended Sep 18, 2022 · High confidence | Lapsed on the fee record | Ended Sep 18, 2022 | High confidence |
| 14/941,529 | Fusion Proteins With Dual Receptor Agonist Activities Abandoned Abandoned May 30, 2018 | Abandoned | Abandoned May 30, 2018 |